Tofacitinib is a selective 1/3 janus kinase inhibitor (JAKi), used to treat a number of inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, psoriasis, atopic dermatitis, systemic lupus, sarcoidosis, vitiligo, and alopecia areata (AA). 1,2 Tofacitinib inhibits signaling of numerous cytokines including interferon (IFN)-γ, interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21, thereby attenuating the inflammatory cascade and activation of T cells involved in AA pathogenesis. 3,4 Alopecia areata is an autoimmune, non-scaring alopecia with an estimated lifetime prevalence of 2%. 5 Almost half of all patients experience disease onset within the first two decades of life making it the most common cause of hair loss in children. 6 The natural history of
This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.